CHIRAL SYNTHESIS OF N-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]-6-METHOXYPHENYL}-1-[2,3-DIHYDROXY-PROPYL]CYCLOPROPANESULFONAMIDES

(19)

(11)

EP 2 714 652 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	05.09.2018 Bulletin 2018/36

(45)	Mention of the grant of the patent:
	18.07.2018 Bulletin 2018/29

(21)	Application number: 12723865.7

(22)	Date of filing: 24.05.2012

(51)

International Patent Classification (IPC):

C07C 303/38^(2006.01)
C07C 309/82^(2006.01)

C07C 303/40^(2006.01)
C07C 311/28^(2006.01)

(86)	International application number:
	PCT/EP2012/059717

(87)	International publication number:
	WO 2012/163799 (06.12.2012 Gazette 2012/49)

(54)

CHIRAL SYNTHESIS OF N-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]-6-METHOXYPHENYL}-1-[2,3-DIHYDROXY-PROPYL]CYCLOPROPANESULFONAMIDES

CHIRALE SYNTHESE VON {N- [3,4-DIFLUOR-2- (2-FLUOR-4-IODOPHENYL)] AMINO} -6-METHOXYPHENYL -1- [2,3-DIHYDROXY-PROPYL] CYCLOPROPANSULFONAMIDE

SYNTHÈSE CHIRALE DE N-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHÉNYL)AMINO]-6-MÉTHOXYPHÉNYL}-1-[2,3-DIHYDROXY-PROPYL]CYCLOPROPANESULFONAMIDES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(30)

Priority:

27.05.2011 EP 11167806

(43)	Date of publication of application:
	09.04.2014 Bulletin 2014/15

(73)	Proprietor: Ardea Biosciences, Inc.
	San Diego CA 92121 (US)

(72)	Inventors:
	FEY, Peter 42111 Wuppertal (DE) MAYER, Agathe, Christine 50670 Köln (DE)

(74)	Representative: HGF Limited
	4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG Manchester M1 5WG (GB)

(56)

References cited: :

WO-A1-2011/009541

US-A1- 2008 058 340

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).